Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility
Sharps Technology (NASDAQ: STSS and STSSW) has entered into a transformative five-year sales agreement with a prominent U.S.-based medical products company to supply 10mL SoloGard syringes from its EU facility. This deal is valued at over $50 million and fully utilizes the current production capacity of the Hungary plant.
The agreement follows successful evaluations amid FDA recalls and tariffs on Chinese syringes. It marks a significant milestone, exceeding commitments made in a June 2022 shareholder letter and laying a foundation for future expansion. Initial shipments are slated for November 2024, with a phased ramp-up in 2025. The deal ensures Sharps' products meet growing industry demand driven by diverse therapeutic needs and regulatory challenges facing Chinese suppliers.
Sharps Technology (NASDAQ: STSS e STSSW) ha stipulato un accordo commerciale trasformativo della durata di cinque anni con una rinomata azienda americana di prodotti medicali per fornire siringhe SoloGard da 10 mL dalla sua sede nell'UE. Questo accordo è valutato oltre 50 milioni di dollari e sfrutta appieno la capacità produttiva attuale dello stabilimento ungherese.
L'accordo segue valutazioni positive in un contesto di richiami da parte della FDA e dazi sulle siringhe cinesi. Rappresenta un traguardo significativo, superando gli impegni assunti in una lettera agli azionisti di giugno 2022 e ponendo le basi per future espansioni. Le prime spedizioni sono previste per novembre 2024, con un aumento graduale della produzione nel 2025. L'accordo garantisce che i prodotti di Sharps soddisfino la crescente domanda dell'industria, alimentata da diverse esigenze terapeutiche e dalle sfide normative che affrontano i fornitori cinesi.
Sharps Technology (NASDAQ: STSS y STSSW) ha firmado un acuerdo de ventas transformador de cinco años con una destacada empresa estadounidense de productos médicos para suministrar jeringas SoloGard de 10 mL desde su instalación en la UE. Este acuerdo está valorado en más de 50 millones de dólares y utiliza completamente la capacidad de producción actual de la planta en Hungría.
El acuerdo sigue a evaluaciones exitosas en medio de retiradas de productos de la FDA y aranceles sobre jeringas chinas. Marca un hito significativo, superando los compromisos asumidos en una carta a los accionistas de junio de 2022 y sentando las bases para futuras expansiones. Los envíos iniciales están programados para noviembre de 2024, con un aumento gradual en 2025. El acuerdo asegura que los productos de Sharps satisfagan la creciente demanda de la industria impulsada por diversas necesidades terapéuticas y los desafíos regulatorios que enfrentan los proveedores chinos.
Sharps Technology (NASDAQ: STSS 및 STSSW)는 미국의 저명한 의료 제품 회사와 10mL SoloGard 주사기를 유럽 시설에서 공급하기 위한 5년간의 획기적인 판매 협약을 체결했습니다. 이 거래는 5000만 달러 이상의 가치를 지니며 헝가리 공장의 현재 생산 능력을 최대한 활용합니다.
이 협정은 FDA의 리콜과 중국 주사기에 대한 관세가 부과되는 가운데 성공적인 평가 후에 체결되었습니다. 이는 2022년 6월 주주 서한에서 약속했던 것을 초과하며 향후 확장을 위한 기초를 다지는 중요한 이정표가 됩니다. 초기 배송은 2024년 11월로 예정되어 있으며, 2025년에 단계적으로 생산량을 늘릴 계획입니다. 이 거래는 Sharps의 제품이 다양한 치료적 요구와 중국 공급업체가 직면한 규제 문제로 인해 증가하는 산업 수요를 충족하도록 보장합니다.
Sharps Technology (NASDAQ: STSS et STSSW) a conclu un accord de vente transformateur d'une durée de cinq ans avec une entreprise américaine de produits médicaux de premier plan pour fournir des seringues SoloGard de 10 mL depuis son installation en Europe. Cet accord est évalué à plus de 50 millions de dollars et utilise pleinement la capacité de production actuelle de l'usine hongroise.
L'accord fait suite à des évaluations réussies au milieu de rappels de la FDA et de droits de douane sur les seringues chinoises. Il représente une étape importante, dépassant les engagements pris dans une lettre aux actionnaires de juin 2022 et posant les bases d'une expansion future. Les premières expéditions sont prévues pour novembre 2024, avec une augmentation progressive en 2025. L'accord garantit que les produits de Sharps répondent à la demande croissante du secteur, alimentée par divers besoins thérapeutiques et les défis réglementaires auxquels sont confrontés les fournisseurs chinois.
Sharps Technology (NASDAQ: STSS und STSSW) hat einen transformierenden Verkaufsvertrag über fünf Jahre mit einem renommierten US-amerikanischen Medizintechnikunternehmen abgeschlossen, um 10mL SoloGard-Spritzen aus seiner EU-Anlage zu liefern. Dieser Vertrag hat einen Wert von über 50 Millionen Dollar und nutzt die aktuelle Produktionskapazität des ungarischen Werks vollständig aus.
Der Vertrag folgt erfolgreichen Bewertungen inmitten von Rückrufen durch die FDA und Zöllen auf chinesische Spritzen. Er markiert einen wichtigen Meilenstein, der die in einem Schreiben an die Aktionäre im Juni 2022 gegebenen Verpflichtungen übertrifft und die Grundlage für zukünftige Expansionen legt. Die ersten Lieferungen sind für November 2024 geplant, mit einem schrittweisen Anstieg der Produktion im Jahr 2025. Der Vertrag stellt sicher, dass die Produkte von Sharps die steigende Nachfrage der Branche erfüllen, die durch verschiedene therapeutische Bedürfnisse und die regulatorischen Herausforderungen für chinesische Anbieter beeinflusst wird.
- Five-year sales agreement valued at over $50 million.
- Full utilization of the Hungary plant's current production capacity.
- Initial shipments planned for November 2024, ramping up in 2025.
- Exceeding commitments made in the June 2022 shareholder letter.
- Potential dependency on a single large client for a significant portion of revenue.
This news is highly impactful for Sharps Technology (NASDAQ: STSS). The company has secured a five-year sales agreement with a major U.S. medical products supplier, which is expected to generate over
Key financial implications include:
- Guaranteed revenue stream: The agreement ensures a steady income for at least five years, providing financial stability and predictability.
- Production capacity utilization: Full utilization of the EU facility's capacity indicates efficient operations and potential for economies of scale.
- Growth catalyst: The deal necessitates near-term expansion, suggesting future capital expenditures and potential for further revenue growth.
- Market positioning: This agreement strengthens Sharps' position as an alternative to Chinese manufacturers, potentially opening doors for more contracts in the future.
Investors should note that revenue recognition is expected to begin in Q4 2024, with a phased ramp-up into 2025. This timeline gives the company a clear path to near-term revenue growth. However, it's important to monitor the company's ability to meet production demands and manage the anticipated expansion efficiently.
The significance of this deal for Sharps Technology extends beyond mere financial gains. It represents a strategic shift in the medical device industry, particularly in light of recent FDA recalls and tariffs on Chinese-supplied syringes. This development highlights several key industry trends:
- Increasing demand for non-Chinese medical supplies: The customer's decision to switch to Sharps' products indicates a growing preference for alternative suppliers, potentially driven by quality concerns and geopolitical factors.
- Rising importance of safety features: Sharps' SecureGard and SoloGard product lines, which incorporate active safety features and re-use prevention measures, align with the industry's focus on patient and healthcare worker safety.
- Expansion of injectable therapies: The company's assertion about the growing need for innovative injection solutions is supported by the increasing use of injectables in various therapeutic areas, including vaccines, biologics and gene therapies.
From a research perspective, this deal validates Sharps' technology and manufacturing capabilities. The successful evaluation of their SoloGard syringes by a prominent U.S. supplier suggests that their products meet high quality standards. This could pave the way for further adoption of Sharps' technology in the healthcare industry, potentially leading to additional contracts and partnerships in the future.
This deal signifies a significant shift in the medical supply chain landscape, with far-reaching implications for the industry. Key market insights include:
- Reshoring trend: The agreement reflects a growing trend of U.S. companies seeking domestic or allied nation suppliers, moving away from Chinese manufacturers. This shift could reshape global supply chains in the medical device sector.
- Market opportunity: Sharps is capitalizing on the void left by Chinese suppliers, suggesting a substantial market opportunity for companies that can offer high-quality alternatives.
- Competitive advantage: By securing this long-term agreement, Sharps has positioned itself as a reliable alternative to Chinese manufacturers, potentially giving it a first-mover advantage in this shifting market.
- Industry consolidation: The deal may trigger similar moves by other U.S. medical suppliers, potentially leading to industry consolidation as companies seek secure, long-term supply agreements.
The market for injectable drug delivery systems is expanding rapidly, driven by the growth in biologics, vaccines and other injectable therapies. Sharps' ability to secure this deal positions them well to capture a significant share of this growing market. However, the company will need to manage its growth carefully, ensuring it can meet increased demand while maintaining product quality and expanding its production capacity.
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future
Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes
Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps’ facility in the EU. The customer initiated an evaluation of Sharps’ SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.
“Creating a strategic partnership with the customer and selling out production capacity at the Hungary plant for the next five years is a historic accomplishment for Sharps and the future success of the Company,” stated Robert Hayes, CEO of Sharps Technology. “The collaboration creates a five-year sales agreement for at least 500 million syringes and essentially consumes the current available manufacturing capacity for Sharps’ 10mL SoloGard disposable syringe. This project also provides a clear path for near-term revenue for our company beginning in Q4 2024, with a phased ramp up into 2025.”
Filippo Filippi, General Manager of the SafeGard manufacturing facility, is pleased that his plant is delivering on commitments made by Sharps leadership in 2022. “We have been driven to bring our innovative syringes to the U.S. healthcare market,” says Filippi. “After two years of dedicated efforts, I am excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year. Equally as important, this sales agreement will help provide a solid foundation for the continued expansion of Sharps’ European division in Hungary.”
The Company believes that the need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese supplied syringes, Sharps is seeing increasing levels of interest and potential demand for its high-quality smart safety syringe products. Specializing in the development and manufacturing of innovative drug delivery systems, Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features, as well as World Health Organization accredited re-use prevention measures.
About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and is partnering with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For more information about Sharps Technology, please visit the website at: http://sharpstechnology.com.
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-644-4256
STSS@redchip.com
FAQ
What is the value of Sharps Technology's new sales agreement?
When will Sharps Technology begin shipping the 10mL SoloGard syringes?
What led to the execution of the sales agreement for Sharps Technology's syringes?
What is the production capacity status of Sharps Technology's Hungary facility?
How does the new sales agreement align with Sharps Technology's previous commitments?
